ESG Intelligence – Pharmaceuticals – 1st December 2020 to 28th February 2021
The average ESG score (-20) for companies across the sector declines significantly in comparison to the previous three-month period. ‘Affordability & Pricing’ dominates discussion in late-January due to multiple price hikes across the sector, and again in mid-February as several companies refuse to sell therapies at the legally required 340B price; 12 firms score negatively on this issue. Biogen & Roche lawsuits contribute negatively to ‘Business Ethics’ with bribery and corruption claims against a number of firms prevalent in social media coverage. Praise for Covid vaccination research and collaborations notably drops off.
Download the full report here.
Register below to receive alva’s ESG Intelligence Report: